Feed ARCT
AR

Arcturus Therapeutics Holdings Inc.

ARCT · NASDAQ

$13.30 -7.89% (-$1.14)
1M -13.86%
Market Cap $378.0M
P/E Ratio -
Div. Yield -
ROE 46.54%
Piotroski F-Score Weak
1/9
Valuation
41 /100
Fair
P/S 15.88x
P/B 2.20x
P/E N/A
Growth
0 /100
Declining
Rev. growth 31.13%
Book val. growth 7.49%
EPS growth N/A
Profitability
20 /100
Weak
Gross margin 83.19%
FCF margin 306.91%
Net margin 391.90%
Quality
1 /100
Poor
ROIC 52.96%
Asset turnover 0.11x
ROE 46.54%
Debt
100 /100
Low
Debt/Equity 0.13x
Current ratio 5.88x
Int. coverage N/A
Stability
18 /100
Unstable
Beta 2.48x
Profitable years 0
Rev. volatility 20.19%

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o ARCT
Online

O podjetju

Arcturus Therapeutics Holdings Inc. (ARCT) is an American biotechnology company specializing in the development and research of messenger RNA (mRNA)-based therapeutics. With innovative approaches to treating diseases, including infectious diseases and genetic disorders, Arcturus Therapeutics Holdings Inc. is a key player in the field of biotechnology. The company focuses on harnessing mRNA for the development of novel therapeutic solutions. Arcturus Therapeutics Holdings Inc. (ARCT) shares could be suitable for investors looking to invest in the biotechnology sector with innovative and promising therapeutic approaches.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Joseph E. Payne

Employees

109

Headquarters

San Diego

Prihajajoči dogodki

09 NOV.

Earnings

Upcoming earnings report

46d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.